Latin America Short- and Long-Read NGS Market: Focus on Product Type, Workflow, Technology, Application, End User, and Country Analysis Forecast, 2026-2036

This report can be delivered within 1 working day.

Introduction of the Latin America Short- and Long-Read NGS Market

The Latin America short- and long-read NGS market, initially valued at $141.8 million in 2025, is projected to grow substantially, reaching $441.5 million by 2036, with a remarkable compound annual growth rate (CAGR) of 10.90% from 2026 to 2036.

The Latin America short- and long-read NGS market is evolving from a fragmented and externally dependent sequencing landscape toward a more localized, application-driven, and workflow-oriented genomics ecosystem. Short-read sequencing continues to form the backbone of the market because of its established installed base, scalability, cost-efficiency, and broad use in routine clinical and research workflows.

Long-read sequencing and portable nanopore sequencing are gaining selective traction in public health, research, and national institute settings where longer reads, real-time analysis, flexible deployment, and rapid outbreak response provide clear value. The resulting ecosystem is hybrid; short-read platforms support the majority of routine sequencing volume, while long-read technologies complement them in applications requiring longer reads, real-time sequencing, or more complete genome characterization.

The ecosystem includes sequencing platform providers, recurring consumables and workflow suppliers, library preparation and target enrichment providers, bioinformatics and interpretation platforms, and supporting automation and data infrastructure. As laboratories move toward integrated sample-to-report workflows, vendors with strong product ecosystems, local support, training capabilities, and bioinformatics integration are positioned to capture recurring demand.

Market Introduction

The Latin America short- and long-read NGS market is being shaped by the growing burden of cancer and infectious diseases, the increasing use of molecular profiling in oncology, the continued need for pathogen surveillance, and expanding interest in rare disease diagnosis, population genomics, biodiversity research, and precision public health.

Local genomics infrastructure is expanding through public programs, regional surveillance networks, vendor-led training centers, and private laboratory partnerships. Brazil, Mexico, Colombia, Argentina, Chile, and other Latin American countries are gradually building domestic sequencing and bioinformatics capabilities through public health initiatives, national genomics programs, regional reference laboratories, and commercial laboratory adoption.

This shift is increasing demand for sequencing instruments, recurring consumables, library preparation kits, flow cells, sequencing reagents, automation systems, data platforms, and interpretation software. However, bioinformatics capacity gaps, skilled workforce shortages, workflow validation challenges, sample quality issues, and uneven access to advanced sequencing infrastructure remain constraints.

Industrial Impact

The Latin America short- and long-read NGS market is being shaped by a multi-layered competitive landscape comprising sequencing platform vendors, workflow support companies, and bioinformatics providers. In short-read sequencing, Illumina, Inc., Thermo Fisher Scientific Inc., and MGI Tech Co., Ltd. remain the principal competitors across sequencing-by-synthesis, semiconductor sequencing, and DNA nanoball sequencing, respectively. At the same time, Oxford Nanopore Technologies plc and Pacific Biosciences of California, Inc. are expanding the long-read segment through differentiated value propositions around real-time sequencing, portability, high-accuracy long reads, and complex genomic analysis, while MGI Tech Co., Ltd.'s CycloneSEQ portfolio introduces an additional nanopore-based pathway into the regional technology landscape.

At the same time, competition is extending beyond sequencing instruments toward the broader NGS workflow, increasing the strategic importance of companies operating across library preparation, target enrichment, automation, data analysis, and interpretation. Agilent Technologies, Inc., QIAGEN N.V., Revvity Inc., Danaher Corporation, and New England Biolabs are positioned across recurring consumables and workflow-support products, while SOPHiA GENETICS SA and QIAGEN N.V. are benefiting from the growing need for scalable bioinformatics and interpretation capabilities. F. Hoffmann-La Roche Ltd. adds another competitive layer through its oncology-focused workflow portfolio and sequencing-by-expansion platform. As Latin American laboratories move from isolated instrument adoption toward more standardized sample-to-report workflows, competitive advantage is expected to increasingly depend on the ability to combine sequencing technology with automation, consumables, bioinformatics, training, and local technical support.

Market Segmentation:

Segmentation 1: By Product Type

• Short-Read NGS Market
  • Consumables
  • Instruments
  • Software
• Long-Read NGS Market
  • Consumables
  • Instruments
  • Software

Consumables Segment to Dominate Latin America Short- and Long-Read NGS Market (by Product Type)

In 2025, consumables are expected to account for the largest share of both the short-read and long-read NGS markets in Latin America. This is primarily driven by their recurring use across every sequencing run, including sequencing reagents, flow cells, library preparation kits, and other workflow-specific consumables. Consumable demand scales directly with sequencing volume and platform utilization. The broader installed base and higher routine testing volumes support consumable demand in short-read sequencing, while the gradual transition of long-read sequencing from pilot studies toward broader research and specialized applications is expected to increase recurring reagent and flow-cell consumption over the forecast period.

Segmentation 2: By Workflow

• Sample Preparation and Library Preparation
• Sequencing
• Analysis

Sequencing Segment to Dominate Latin America Short- and Long-Read NGS Market (by Workflow)

In 2025, on the basis of workflow, sequencing is expected to capture the largest share of the Latin America short- and long-read NGS market by workflow, as this segment includes the highest-value recurring consumables such as sequencing reagents, flow cells, chips, SMRT Cells, and run-specific kits, along with instrument utilization. In addition to this, data analysis will gain importance as NGS adoption expands, yet its revenue contribution is likely to remain smaller than sequencing and preparation workflows due to lower per-sample monetization and greater use of bundled or platform-linked software.

Segmentation 3: By Technology

• Short-Read Sequencing Technologies
• Long-Read Sequencing Technologies

Short-Read Sequencing Technologies Segment to Dominate Latin America Short- and Long-Read NGS Market (by Technology)

In 2025, on the basis of technology, the short-read sequencing technologies segment is expected to capture the largest share of the Latin America short- and long-read NGS market. This is supported by the broader installed base, higher routine sequencing volumes, lower cost per sample, and wider use of short-read platforms across oncology, infectious disease, reproductive health, inherited disease, and research applications. Short-read sequencing also benefits from a mature ecosystem of consumables, library preparation products, target enrichment panels, and bioinformatics tools, which supports recurring demand across laboratories. Long-read sequencing is expected to grow at a faster pace in specialized applications such as structural variant analysis, complex genome assembly, rare disease research, and pathogen genomics; however, its share is likely to remain smaller due to a more limited installed base, higher workflow complexity, and concentration in advanced research and translational genomics centers.

Segmentation 4: By Method

• Whole-Genome Sequencing
• Whole-Exome Sequencing
• RNA Sequencing
• Epigenetic Sequencing
• Targeted Sequencing
• Metagenomic Sequencing
• Others

Whole-Genome Sequencing Segment to Dominate Latin America Short- and Long-Read NGS Market (by Method)

In 2025, on the basis of method, whole-genome sequencing is expected to capture the largest share of the Latin America short- and long-read NGS market. This is supported by its broad use across population genomics, oncology research, rare disease studies, infectious disease surveillance, microbial genomics, agricultural genomics, and biodiversity programs, along with higher sequencing-output requirements per sample compared with exome, RNA, epigenetic, and metagenomic workflows. Whole genome sequencing also benefits from adoption across both short-read and long-read platforms, making it relevant to a wider range of instrument and consumable portfolios. Whole exome sequencing is expected to remain important in clinical genetics and rare disease applications, while RNA sequencing, epigenetic sequencing, and metagenomics are likely to grow from a smaller base due to their more specialized use cases.

Segmentation 5: By Application

• Clinical
• Research

Research Segment to Dominate Latin America Short- and Long-Read NGS Market (by Application)

In 2025, on the basis of application, research applications are expected to capture the larger share of the Latin America short- and long-read NGS market due to the region's strong reliance on academic institutions, government-funded genomics programs, and pharmaceutical research for applications such as cancer genomics, infectious disease surveillance, and population genetics. In contrast, routine clinical adoption remains comparatively limited because of reimbursement constraints, uneven access to genomic testing, and the gradual integration of NGS into standard healthcare practice across many Latin American countries.

Segmentation 6: By End User

• Hospitals and Diagnostic Centers
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Others

Academic and Research Institutes Segment to Dominate Latin America Short- and Long-Read NGS Market (by End User)

In 2025, on the basis of end user, academic and research institutes are expected to capture the largest value share of the Latin America short- and long-read NGS market owing to substantial government and international funding for genomics research, infectious disease surveillance, cancer genomics, and population genetics. Furthermore, a significant proportion of high-throughput sequencing infrastructure in the region is concentrated within universities and public research organizations, making them the primary users of NGS technologies.

Recent Developments in the Latin America Short- and Long-Read NGS Market

• In May 2026, MGI Tech Co., Ltd. launched integrated SEQ ALL metagenomic solutions for Andes Hantavirus response, combining DNBSEQ short-read sequencing with CycloneSEQ long-read sequencing. The offering positioned MGI across both short- and long-read infectious disease surveillance workflows and expanded its application relevance for Latin American public health genomics.
• In March 2026, MGI Tech Co., Ltd. partnered with NeoGenomica to expand access to high-throughput genomics in Brazil. The collaboration used DNBSEQ-T7 and MGISP automation and included technical training, knowledge exchange, and best-practice support, which helped scale whole-genome, oncology, and rare disease sequencing capacity.
• In November 2025, SOPHiA GENETICS SA participated in AMGH 2025 in Puerto Vallarta, Mexico, covering the Mexican Association of Human Genetics Congress and the Latin American Congress of Human Genetics. The company showcased SOPHiA DDM to regional genetics stakeholders, which supported market education and customer development for NGS data analytics in Latin America.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

• Rising Cancer and Infectious Disease Burden Driving Demand for Next-Generation Sequencing and Associated Products: The increasing burden of cancer and infectious diseases is creating sustained demand for NGS products across Latin America. Oncology is driving clinical demand through molecular tumor profiling, DNA/RNA panels, WES/WGS, liquid biopsy, hereditary cancer testing, and variant interpretation software. Infectious diseases are strengthening public health demand for pathogen sequencing, dengue serotype monitoring, tuberculosis resistance profiling, outbreak investigation, antimicrobial resistance characterization, and genomic surveillance. As testing and surveillance volumes expand, the Latin America short- and long-read NGS market is expected to see recurring demand for sequencing reagents, flow cells, library preparation kits, sample preparation products, quality-control materials, and NGS-specific bioinformatics platforms. Overall, the disease burden across oncology and infectious diseases is expected to remain a key driver of demand for NGS instruments, consumables, and software in the region.
• Expansion of Local Genomics Infrastructure through Public Programs, Vendor Hubs, and Strategic Partnerships: The recent developments across Brazil, Colombia, Mexico, and Argentina show that local infrastructure expansion is becoming an active demand driver for the Latin America NGS market. Public programs such as Genomas Brasil, GenSUS, and SUS whole-exome sequencing are institutionalizing genomics within public health and precision medicine, creating sustained demand for sequencing capacity and interpretation tools. Vendor-led centers from MGI Tech Co., Ltd. and Illumina are improving customer readiness through local training, demonstrations, automation access, workflow evaluation, and technical support. Private partnerships such as MGI-Gencell and SOPHiA-Argenetics indicate that commercial laboratories are scaling sequencing and analytics capacity for WES, WGS, oncology, and hematology workflows. Together, these developments are strengthening the regional NGS installed base and increasing recurring demand for instruments, consumables, automated sample preparation systems, and NGS-specific software.
• Expansion of Local Genomic Data Generation and Population-Scale Sequencing Programs Driving NGS Adoption: For the Latin America short- and long-read NGS market, population-scale genomic data generation drives demand across the full sequencing workflow. National genomic databases, rare disease cohorts, oncology datasets, pharmacogenomics studies, and public health genomics programs require sample preparation products, library preparation kits, sequencing reagents, flow cells, WES/WGS workflows, automation systems, data storage platforms, bioinformatics pipelines, variant curation tools, and interpretation software. The impact extends beyond one-time instrument placement, as ongoing genomic dataset development creates recurring demand for consumables, sequencing runs, quality-control materials, software, and data-management infrastructure. As these programs expand, NGS adoption is expected to strengthen across public health programs, research institutions, reference laboratories, and specialized clinical centers in Latin America.

Market Challenges

• Bioinformatics, Skilled Workforce, and Workflow Implementation Gaps Limiting NGS Scalability: Bioinformatics, workforce, and workflow readiness gaps limit both the adoption of new NGS platforms and the utilization of installed systems in Latin America. These constraints reduce the market's ability to convert clinical, research, and public health demand into sustained product usage. As a result, the restraint directly affects pull-through demand for sequencing reagents, flow cells, library preparation kits, sample preparation products, quality-control materials, and NGS-specific software. Wider adoption of NGS across the region will require parallel investment in technical training, bioinformatics infrastructure, workflow standardization, sample quality management, and clinical reporting capacity.

Market Opportunities

• Expansion of Integrated Sample-to-Report NGS Workflow Bundles for Latin American Laboratories: Integrated sample-to-report NGS workflow solutions represent a high-value product opportunity in Latin America. The region's laboratories are increasingly looking for solutions that reduce operational complexity and enable scalable sequencing across clinical and research applications. Workflow-led models that combine sequencers, automation systems, data platforms, bioinformatics, training, and local support can help laboratories improve throughput and reduce dependence on external sequencing providers. For vendors, the opportunity extends beyond one-time instrument sales and creates recurring revenue potential across consumables, reagents, flow cells, automation products, software, data platforms, and service support.

How can this report add value to an organization?

Product/Innovation Strategy: The Latin America short- and long-read NGS market has been segmented across product type, workflow, technology, method, application, end user, and country. This segmentation helps organizations assess demand across short- and long-read instruments, consumables, and software, while also evaluating adoption across sample and library preparation, sequencing, and data-analysis workflows. By examining technology-level opportunities across sequencing-by-synthesis, semiconductor sequencing, DNA nanoball sequencing, SMRT sequencing, and nanopore sequencing, alongside methods such as whole-genome sequencing, whole-exome sequencing, RNA sequencing, epigenetic sequencing, targeted sequencing, and metagenomics.

Growth/Marketing Strategy: The Latin America short- and long-read NGS market is being driven by the localization of genomic testing, expansion of public and private sequencing infrastructure, increasing cancer and infectious disease burden, population-scale genomic programs, and growing adoption of sequencing across research, public health, and selected clinical applications. The report helps organizations identify high-potential customer groups and application areas, prioritize markets such as Brazil, Mexico, Argentina, Chile, and Colombia, and assess opportunities across academic and research institutes, hospitals and diagnostic centers, pharmaceutical and biotechnology companies, and other end users.

Competitive Strategy: The Latin America short- and long-read NGS market includes sequencing-platform companies, long-read specialists, workflow-support companies, and bioinformatics providers competing across instruments, consumables, software, and data interpretation. The report helps organizations benchmark competitor positioning across short-read and long-read technologies, assess differences in throughput, workflow simplicity, installed-base expansion, and local support, and identify opportunities for partnerships, portfolio expansion, and workflow integration. It also supports competitive decision-making by outlining how differentiation is shifting from instrument placement alone toward integrated workflows, recurring consumables, automation, bioinformatics, turnaround time, training, and technical service as laboratories move toward more complete sample-to-report NGS ecosystems.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2036 have been considered for the Latin America short- and long-read NGS market. For market size estimation, 2025 has been considered the base year, and 2026 to 2036 the forecast period.
• Data on the portability type was considered from national and international organizations.
• Publicly traded companies involved in the development of medical image analytics solutions also provided data.
• Industry research papers, patents, and advancements in related technologies highlighted emerging trends and growth opportunities in the market. Proxy indicators were employed where direct data were unavailable.
• Databases such as Bloomberg and governmental statistical portals offering insights on raw material usage, innovative technologies, and market trends were extensively utilized.
• Technologies currently used are expected to persist through the forecast period 2026-2036.
• The economic downturn in the future was not taken into consideration for market estimation and forecast.

Primary Research

The primary sources involve industry experts and key stakeholders across the healthcare and medical imaging ecosystem, including medical image analytics providers, medical device manufacturers, radiology service providers, and healthcare institutions. Stakeholders such as hospitals, imaging centers, and teleradiology providers have been consulted to validate adoption trends and clinical utility. Respondents, including CEOs, vice presidents, product and marketing directors, and technology and innovation leaders, have been interviewed to obtain and verify both qualitative and quantitative insights for this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors' presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• MGI Tech Co., Ltd.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Revvity Inc.
• QIAGEN N.V.
• Danaher Corporation
• SOPHiA GENETICS SA
• New England Biolabs